About Fortress biotech
Fortress Biotech: A Leading Biopharmaceutical Company
Fortress Biotech, Inc. is a renowned biopharmaceutical company that has been making waves in the industry for its innovative approach to drug development and research. The company has been ranked in Deloitte's 2019 and 2020 Technology Fast 500™, which is an annual ranking of the fastest-growing North American companies in technology.
Founded in 2006, Fortress Biotech has quickly established itself as a leader in the biopharmaceutical industry. The company's mission is to develop and commercialize novel pharmaceuticals that address unmet medical needs. With a focus on oncology, rare diseases, and gene therapy, Fortress Biotech aims to improve patient outcomes by developing innovative treatments.
One of the key strengths of Fortress Biotech is its unique business model. The company operates through a network of subsidiary companies that are focused on specific therapeutic areas or technologies. This allows each subsidiary to have dedicated resources and expertise while benefiting from shared services such as finance, legal, and regulatory affairs.
Fortress Biotech's subsidiaries include:
1) Aevitas Therapeutics - focused on developing gene therapies for rare genetic diseases
2) Caelum Biosciences - developing treatments for cancer and other serious diseases
3) Checkpoint Therapeutics - developing immunotherapy treatments for cancer
4) Journey Medical Corporation - focused on dermatology products
5) Mustang Bio - developing cell-based therapies for cancer
Through these subsidiaries, Fortress Biotech has built an impressive pipeline of drug candidates at various stages of development. Some notable candidates include MB-107 (a gene therapy for X-linked severe combined immunodeficiency), CAEL-101 (a treatment for amyloidosis), CK-301 (an anti-PD-L1 antibody), among others.
In addition to its strong pipeline of drug candidates, Fortress Biotech also boasts an experienced management team with deep expertise in drug development and commercialization. Led by CEO Dr. Lindsay Rosenwald, who has over 25 years of experience in the biopharmaceutical industry; this team brings together decades of experience across all aspects of drug development from discovery through commercialization.
Furthermore; Fortress' commitment towards innovation extends beyond just its research efforts but also towards improving healthcare delivery systems globally through strategic partnerships with leading academic institutions like Columbia University Medical Center & Mount Sinai Health System among others.
Overall; Fortress' unique business model coupled with its strong pipeline makes it one of the most promising biopharmaceutical companies today with potential breakthroughs that could change lives around the world.
In conclusion; if you're looking to invest or partner with a leading-edge biopharma firm then look no further than Fortress!